Novo Nordisk’s Q2 2025 shows strong growth despite competition. See more on NVO's key catalysts and price targets driving ...

HSBC made the call as it listed the pharma stocks it sees as best positioned to play a recovery in the sector.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Novo Nordisk is well-positioned in the obesity drug market, with strong financials and anticipation for its oral Wegovy pill.

Novo Nordisk (NYSE:NVO) shares have moved little in recent sessions, with investors taking a wait-and-see approach. Market participants are weighing the company's recent performance metrics against ...

Novo Nordisk (NVO) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some ...

In recent weeks Novo Nordisk has secured several key label expansions for some of its products, which should contribute ...

Novo Nordisk has cut dozens of jobs at its Clayton, North Carolina site, part of a global restructuring as it faces slowing ...

Morgan Stanley has downgraded Novo Nordisk, whose U.S. shares are already down a third this year. That downgrade forecasts ...

If you’re holding Novo Nordisk stock or considering jumping in, you’ve probably watched its recent moves with more than a little curiosity. Novo Nordisk may not be a household name on every street, ...

In the most recent trading session, Novo Nordisk (NVO) closed at $60.71, indicating a -1.12% shift from the previous trading ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...